Jump to main content
Jump to site search


Human serum albumin-based doxorubicin prodrug nanoparticles with tumor pH-responsive aggregation-enhanced retention and reduced cardiotoxicity

Author affiliations

Abstract

Doxorubicin (DOX) is a widely-used anticancer drug, but its cardiotoxicity severely hampers its potency in chemotherapy. Herein, human serum albumin (HSA) is engaged as a biocompatible nanocarrier to load a pH-sensitive DOX prodrug, DMDOX, generating HSA–DMDOX nanoparticles via self-assembly driven by hydrophobic interactions. HSA–DMDOX disperses well in a physiological environment (∼40 nm) but aggregates in a tumor acidic microenvironment (pH 6.5, ∼140 nm) owing to the hydrophobicity increase of DMDOX by protonation of carboxylic groups. In vitro anticancer study showed that HSA–DMDOX exhibited enhanced cellular uptake by 4T1 cells and superior cytotoxicity in comparison to HSA–DOX nanoparticles. In vivo study suggested that HSA–DMDOX achieved long blood circulation, aggregation enhanced tumor retention, comparable antitumor efficacy and reduced cardiotoxicity relative to free DOX. Our work presents a facile and effective approach to delivering anthracyclines by HSA-based tumor pH-responsive nanoparticles with aggregation-enhanced tumor retention and reduced toxicity.

Graphical abstract: Human serum albumin-based doxorubicin prodrug nanoparticles with tumor pH-responsive aggregation-enhanced retention and reduced cardiotoxicity

Back to tab navigation

Supplementary files

Article information


Submitted
06 Feb 2020
Accepted
25 Mar 2020
First published
25 Mar 2020

J. Mater. Chem. B, 2020, Advance Article
Article type
Paper

Human serum albumin-based doxorubicin prodrug nanoparticles with tumor pH-responsive aggregation-enhanced retention and reduced cardiotoxicity

B. Zhang, S. Wan, X. Peng, M. Zhao, S. Li, Y. Pu and B. He, J. Mater. Chem. B, 2020, Advance Article , DOI: 10.1039/D0TB00327A

Social activity

Search articles by author

Spotlight

Advertisements